

# Gilead Sciences, Inc Product Pipeline Review 2016

*'Gilead Sciences, Inc. - Product Pipeline Review - 2016', provides an overview of the Gilead Sciences, Inc.'s pharmaceutical research and development focus.*

PUNE, INDIA, April 14, 2016 /EINPresswire.com/ -- The report "[Gilead Sciences, Inc. - Product Pipeline Review - 2016](#)" provides comprehensive information on the therapeutics under development by F. Hoffmann-La Roche Ltd., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Access a Report Copy @ <https://www.wiseguyreports.com/reports/gilead-sciences-inc-product-pipeline-review-2016> .

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.



Note\*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

## Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Gilead Sciences, Inc.
- The report provides overview of Gilead Sciences, Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Gilead Sciences, Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Gilead Sciences, Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Purchase a 1-User License Copy @

[https://www.wiseguyreports.com/checkout?currency=one\\_user-USD&report\\_id=393572](https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=393572) .

## Reasons to buy

- Evaluate Gilead Sciences, Inc.'s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Gilead Sciences, Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Gilead Sciences, Inc.'s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Major Point in Table of Content

Gilead Sciences, Inc. - Drug Profiles 25

(emtricitabine + rilpivirine hydrochloride + tenofovir alafenamide) 25  
(emtricitabine + tenofovir alafenamide fumarate) 26  
(sofosbuvir + velpatasvir) 27  
tenofovir alafenamide 30  
(cobicistat + elvitegravir + emtricitabine + tenofovir alafenamide fumarate) 32  
(emtricitabine + GS-9883 + tenofovir alafenamide) 34  
(GS-9857 + sofosbuvir + velpatasvir) 35  
ambrisentan 37  
eleclazine 39  
GS-5745 41  
idelalisib 43  
mometinib dihydrochloride 46  
acalisib 49  
entospletinib 50  
GS-4774 51  
presatovir 52  
ranolazine ER 53  
regadenoson 56  
selonsertib 58  
selonsertib + simtuzumab 59  
simtuzumab 60  
vesatolimod 62  
GS-5829 64  
GS-5734 65  
GS-9674 66  
GS-9876 68  
ONO-4059 69  
GS-459679 71  
GS-548202 72  
GS-5759 73  
GS-607601 74  
GS-8374 75  
GS-967 76  
GS-986 77  
Monoclonal Antibodies 1 for Oncology 78  
Monoclonal Antibody for HIV / AIDS 79  
Monoclonal Antibody to Target HIV-Envelope and CD3 for HIV 80  
Px-103 81  
Small Molecule to Inhibit Histone Deacetylation for Oncology 82  
Small Molecule to Inhibit Histone Methyltransferase for Oncology 83  
GS-563253 84  
GS-599220 85  
Small Molecule for RSV 86

Small Molecule to Inhibit NS4B Protein for HCV 87

Small Molecules for Hepatitis C Infection 88

Small Molecules to Inhibit NS3 Protease for Hepatitis C 89

Small Molecules to Inhibit NS5B for Hepatitis C 90

Inquire for more information @ <https://www.wiseguyreports.com/enquiry/gilead-sciences-inc-product-pipeline-review-2016> .

Norah Trent

WiseGuy Research Consultants Pvt. Ltd.

16468459349

[email us here](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/321380112>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.